Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.73 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.73 |
| ▸ | MAPT | P10636 | 3/20 | 0.73 |
| ▸ | USP2 | O75604 | 2/20 | 0.73 |
| ▸ | TP53 | P04637 | 2/20 | 0.73 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.73 |
| ▸ | HPGD | P15428 | 1/20 | 0.73 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.73 |
| ▸ | HBB | P68871 | 1/20 | 0.73 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.73 |
| ▸ | FLT3 | P36888 | 2/20 | 0.71 |
| ▸ | IP6K2 | Q9UHH9 | 2/20 | 0.71 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.71 |
| ▸ | APP | P05067 | 6/20 | 0.69 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.66 |
| ▸ | THRB | P10828 | 1/20 | 0.66 |
| ▸ | PLG | P00747 | 1/20 | 0.65 |
| ▸ | MAOB | P27338 | 2/20 | 0.65 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.65 |
| ▸ | PARP1 | P09874 | 3/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sequoiaflavone SCHEMBL30646160 | 1.00 | MEN1 (0.73) | MEN1KMT2AMAPTUSP2TP53 | |
| Podocarpusflavone B SCHEMBL29496271 | 0.96 | MAPT (0.73) | MEN1KMT2AMAPTUSP2TP53 | |
| Podocarpusflavone B SCHEMBL27350627 | 0.96 | MAPT (0.73) | MEN1KMT2AMAPTUSP2TP53 | |
| Podocarpusflavone A SCHEMBL29496316 | 0.92 | MEN1 (0.72) | MEN1KMT2AMAPTUSP2TP53 | |
| Podocarpusflavone A SCHEMBL25937932 | 0.92 | MEN1 (0.72) | MEN1KMT2AMAPTUSP2TP53 | |
| Ginkgetin SCHEMBL30612275 | 0.92 | MAPT (0.86) | MEN1KMT2AMAPTUSP2TP53 | |
| Ginkgetin SCHEMBL31303838 | 0.92 | MAPT (0.86) | MEN1KMT2AMAPTUSP2TP53 | |
| Ginkgetin SCHEMBL888410 | 0.92 | MAPT (0.86) | MEN1KMT2AMAPTUSP2TP53 | |
| Amentoflavone SCHEMBL312563 | 0.89 | MEN1 (0.80) | MEN1KMT2AMAPTUSP2TP53 | |
| Amentoflavone SCHEMBL29497539 | 0.89 | MEN1 (0.80) | MEN1KMT2AMAPTUSP2TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2329831-A2 | Stimulation of hair growth by Ginko biloba flavanoids | Osteoscreen, Inc. (US) | 2011-06-08 | — | — | EP | claimed |
| EP-0126691-B1 | PROCESS FOR PREPARING A THERAPEUTICALLY USEFUL EXTRACT FROM BRACKENRIDGEA ZANGUEBARICA, EXTRACT AND SUCH A MEDICINE | INVERNI DELLA BEFFA S.P.A. (IT) | 1988-04-20 | — | — | EP | claimed |
| EP-0126691-A1 | Process for preparing a therapeutically useful extract from Brackenridgea zanguebarica, extract and such a medicine | INVERNI DELLA BEFFA S.P.A. (IT) | 1984-11-28 | — | — | EP | claimed |
| US-20250228814-A1 | COMBINATION THERAPIES FOR THE TREATMENT OF VIRAL INFECTIONS | FLAGSHIP PIONEERING INNOVATIONS VI, LLC | 2025-07-17 | — | — | US | disclosed |
| WO-2023250111-A1 | COMBINATION THERAPIES FOR THE TREATMENT OF VIRAL INFECTIONS | FLAGSHIP PIONEERING INNOVATIONS VI, LLC (US) | 2023-12-28 | — | — | WO | disclosed |
| US-20230233514-A1 | ANTIVIRAL COMPOUNDS AND METHODS OF USING THE SAME | FLAGSHIP PIONEERING, INC. | 2023-07-27 | — | — | US | disclosed |
| US-20230233514-A1 | ANTIVIRAL COMPOUNDS AND METHODS OF USING THE SAME | FLAGSHIP PIONEERING, INC. | 2023-07-27 | — | — | US | disclosed |
| CN-103141521-B | Cephalotaxus sinensis Li. insecticide and its preparation method | RES & DEV CT OF BIORATIONAL PESTICIDE YANGLING NONGKEDA | 2015-02-18 | — | — | CN | disclosed |
| CN-103141521-A | Cephalotaxus sinensis Li. insecticide and its preparation method | RES & DEV CT OF BIORATIONAL PESTICIDE YANGLING NONGKEDA | 2013-06-12 | — | — | CN | disclosed |
| US-8367121-B2 | Nutraceutical agent for attenuating the neurodegenerative process associated with Parkinson's disease | FLORIDA A & M UNIVERSITY (US) | 2013-02-05 | — | — | US | disclosed |
| EP-1684774-B1 | STIMULATION OF HAIR GROWTH BY ISOGINKGETIN | OSTEOSCREEN INC (US) | 2012-08-29 | — | — | EP | disclosed |
| WO-2003061572-A9 | ANTI-INFLAMMATORY FORMULATIONS | HAINES DAVID (US) | 2004-02-26 | — | — | WO | disclosed |
| US-20030170328-A1 | Anti-inflammatory formulations | NATURAL ALTERNATIVES INTERNATIONAL, INC. | 2003-09-11 | — | — | US | disclosed |
| WO-2003061572-A2 | ANTI-INFLAMMATORY FORMULATIONS | HAINES DAVID (US) | 2003-07-31 | — | — | WO | disclosed |
| EP-1299119-A2 | IMMUNOSUPPRESSIVE COMPOSITIONS COMPRISING AN IMMUNOPHILIN-BINDING COMPOUND AND A GINKGOLIDE COMPOUND | Haines, David (US) | 2003-04-09 | — | — | EP | disclosed |
| US-6328999-B1 | Ginkgo biloba leaf extracts with a reduced 4′-O-methylpyridoxine and biflavone content | DR. WILLMAR SCHWABE GMBH & CO. (DE) | 2001-12-11 | — | — | US | disclosed |
| WO-2001085206-A2 | IMMUNOSUPPRESSIVE COMPOSITIONS COMPRISING AN IMMUNOPHILIN-BINDING COMPOUND AND A GINGKOLIDE COMPOUND | HAINES DAVID (US) | 2001-11-15 | — | — | WO | disclosed |
| EP-0126691-B1 | PROCESS FOR PREPARING A THERAPEUTICALLY USEFUL EXTRACT FROM BRACKENRIDGEA ZANGUEBARICA, EXTRACT AND SUCH A MEDICINE | INVERNI DELLA BEFFA S.P.A. (IT) | 1988-04-20 | — | — | EP | disclosed |
| EP-0126691-A1 | Process for preparing a therapeutically useful extract from Brackenridgea zanguebarica, extract and such a medicine | INVERNI DELLA BEFFA S.P.A. (IT) | 1984-11-28 | — | — | EP | disclosed |
| EP-0126691-A1 | Process for preparing a therapeutically useful extract from Brackenridgea zanguebarica, extract and such a medicine | INVERNI DELLA BEFFA S.P.A. (IT) | 1984-11-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230233514-A1 | ANTIVIRAL COMPOUNDS AND METHODS OF USING THE SAME | ACE2, ACE, EIF2AK2 | MEN1 4255/4885KMT2A 2967/4885MAPT 3743/4885 |
| US-20250228814-A1 | COMBINATION THERAPIES FOR THE TREATMENT OF VIRAL INFECTIONS | HAVCR2, EIF2AK2, MAVS | MEN1 3073/4885KMT2A 3798/4885MAPT 1798/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.